São Paulo, Colombia and Guatemala, June 24, 2024 – Eurofarma, a pharmaceutical company present in 22 countries in Latin America, the United States and some African countries, announces the return of the Genfar brand to Guatemala and Central America. After a brief absence (2019-2023), the brand is returning to the region, initially in Guatemala, Panama, Costa Rica and Honduras, with the aim of continuing to offer top quality and highly effective pharmaceuticals to millions of people in the region.

In 2023, Eurofarma announced the acquisition of 100% of Genfar's representative shares, the largest investment the group has ever made in its history and an important step towards solidifying the company's position in the region. Genfar will be Eurofarma's generic brand for Latin America, except for the Brazilian market. After the relaunch in the first four Central American countries, Genfar's expansion will continue in 2025 in the Dominican Republic, El Salvador and Nicaragua.

Leader in the pure generics market in Colombia, Genfar also has operations in Ecuador and Peru, with a manufacturing plant in Cali. The company has more than 600 employees and offers a robust portfolio of more than 150 molecules and 600 SKUs. By 2023, Genfar will produce more than 1 million products, distributed in 8 countries.

The start of Genfar's regional expansion marks the solidification of Eurofarma's position in Latin America. Founded 52 years ago, the company is the leader in sales of prescription products in the region and in Brazil, where it also ranks second in generics. "We seek to promote timely access to health and quality of life, in line with our purpose of expanding and operating in Central America. With Genfar's return to the region, in these 4 countries, we were able to increase Eurofarma's generic product portfolio by almost three times compared to last year, offering more options to patients and greater coverage of therapeutic areas," said Agustin Vincent, Genfar's General Manager.

"Guatemala, where we already have a plant, is a strategic point for our expansion and for Genfar's arrival in the Central American region," said Francisco Pérez, Eurofarma's General Manager for Central America and the Caribbean. "This partnership underscores the company's commitment to offering innovative, quality products to more people around the world, which are our priorities along with sustainable growth," concludes Rosalba Pantoja, Executive Director of International Operations at Eurofarma.

Genfar's portfolio covers a wide range of therapeutic areas, with prescription and over-the-counter products. Among the categories of medicines that will be sold are analgesics, anti-inflammatories, anti-infectives, dermatological and systemic medicines, as well as products for the nervous system, genitourinary system and cardiovascular system.

Eurofarma in Central America

Eurofarma's plant in Guatemala, which has been in operation since 2013, not only makes its own products, but also offers manufacturing services to third parties. With a floor area of 8,000 m² on a site totaling more than 32,000 m² and almost 490 employees working in the production, commercial and administrative areas, the facility is vital to the company's operations in Latin America. Its focus on quality, innovation and operational excellence highlights the importance of Guatemala in Eurofarma's growth in the region.

This year, Eurofarma celebrates 11 years of operations in Guatemala, with ambitious plans for 2024, which include a 30% increase in production and the launch of 19 products, as well as continuing to work on initiatives that have a positive impact on people's well-being and on social responsibility programs to contribute to the well-being of communities.

About Eurofarma

Established in 1972, Eurofarma operates in the health industry, producing and selling products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as prescription, OTC and personal care, generics, hospital, oncology and animal health, as well as providing production services to third parties. With a broad coverage of therapeutic classes, the portfolio comprises more than 2,000 products and 3,700 SKUs (presentations), serving the main medical specialties.

The leader in medical prescriptions in Latin America and in Brazil, where it is second in generics, Eurofarma is present in 22 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has 12,600 employees and 11 factories, with total production of 573 million units in 2023. In the same year, it invested more than R$680 million in innovation and achieved total net revenue of R$9.1 billion. Over the last 15 years, Eurofarma has recorded average annual growth of 17%.

About Genfar

With 57 years of history, Genfar, a pharmaceutical organization of Colombian origin, is one of the two leading pure generics companies (DCI) in the Colombian, Peruvian and Ecuadorian markets and is among the top 10 companies in the pharmaceutical retail market for the same region. The company has a portfolio of more than 150 molecules and 600 SKUs. Genfar covers a wide range of therapeutic areas and is present in 12 of the most important ones, with medicines for gastrointestinal diseases, diseases of the central nervous system, cardiovascular diseases, diabetes, infectious diseases and over-the-counter medicines, among many others.

The company has a production unit in the city of Cali, as well as the Genfar Lab, a portfolio development and innovation center located in the same city, which was chosen as the winner in the Innovation that Promotes Productive Development in the Health Sector category, as part of the Panorama de Innovación Salud Pinnos project by the Tanque de Pensamiento en Salud - Innos, a joint initiative between Afidro and the HUBiEX of Colombia's El Bosque University, in 2022. Genfar currently has more than 600 employees in Colombia, Peru, Ecuador and Central America and distributes pharmaceuticals to 8 Latin American countries.